Cash Flow Statement

Amortization of Goodwill Amortization of Goodwill Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Net Cash Flow Net Cash Flow Net Income Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Ratios

Zentalis Pharmaceuticals (ZNTL) Change in Receivables (2022 - 2025)

Zentalis Pharmaceuticals has reported Change in Receivables over the past 3 years, most recently at -$5.0 million for Q1 2025.

For Q1 2025, Change in Receivables changed N/A year-over-year to -$5.0 million; the TTM value through Dec 2025 reached -$5.0 million, down 200.0%, while the annual FY2025 figure was -$5.0 million, 200.0% down from the prior year.
Change in Receivables for Q1 2025 was -$5.0 million at Zentalis Pharmaceuticals, down from $5.0 million in the prior quarter.
Over five years, Change in Receivables peaked at $5.0 million in Q4 2024 and troughed at -$5.0 million in Q1 2025.
A 3-year average of $1333.3 and a median of $4000.0 in 2022 define the central range for Change in Receivables.